Inactive Instrument

CanaQuest Medical Corp. Stock Other OTC

Equities

CANQF

CA1372201097

Pharmaceuticals

Sales 2017 - Sales 2018 - Capitalization 1.49M
Net income 2017 -2M Net income 2018 -1M EV / Sales 2017 -
Net Debt 2017 91.34K Net Debt 2018 154K EV / Sales 2018 -
P/E ratio 2017
-1.01 x
P/E ratio 2018
-1.17 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 43.35%
More Fundamentals * Assessed data
Dynamic Chart
NHL Alumni Association Partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in Former NHL Players CI
CanaQuest Medical Corp. cancelled the transaction announced on October 26, 2022 CI
CanaQuest Medical Corp. Announces Award of European Cannabinoid Patent CI
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD CI
CanaQuest Medical Corp. announced a financing transaction CI
CanaQuest Medical Corp. Launches Mentanine (R) (Cannabidiol + IP Formula) in the US CI
CanaQuest Medical Corp. Appoints Rob Rinderman as New Director of Communications CI
Canaquest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre CI
CANAQUEST MEDICAL CORP Announces New Production and Distribution Agreement with PurCann Pharma and SiliCycle Inc CI
CanaQuest Medical Corp. Files A Provisional Cannabidiol/Omega-3 Patent, Trade Named Mentanine® CI
CanaQuest Medical Corp Awaits Health Canada Approval for Sales and Export of Mentabinol® CI
CanaQuest Medical Corp. will Change its Ticker to CANQ.F from ADYNF CI
Algae Dynamics Corp Ordinary Shares will Change its Name to CanaQuest Medical Corporation Ordinary Shares CI
Algae Dynamics Corp. announced that it has received CAD 0.1 million in funding CI
Algae Dynamics Corp. announced that it has received CAD 0.52 million in funding CI
More news
Managers TitleAgeSince
Founder 64 08-10-06
Founder 75 08-10-06
Director of Finance/CFO 76 08-12-31
Members of the board TitleAgeSince
Founder 75 08-10-06
Founder 64 08-10-06
Director/Board Member 58 14-08-27
More insiders
CanaQuest Medical Corporation is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is also focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder (PTSD), including addiction. It provides a novel master formulation derived from cannabidiol (CBD) + IP formula. The Company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the master formulation, branded as Mentanine, is available for sale via the Company’s store in the United States. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects. The Company’s wholly owned subsidiary is ADC BioMedical Corp.
More about the company